Details
Stereochemistry | RACEMIC |
Molecular Formula | C8H18NO2.I |
Molecular Weight | 287.1385 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[I-].CC(C[N+](C)(C)C)OC(C)=O
InChI
InChIKey=LCQWLOBDIMPRBS-UHFFFAOYSA-M
InChI=1S/C8H18NO2.HI/c1-7(11-8(2)10)6-9(3,4)5;/h7H,6H2,1-5H3;1H/q+1;/p-1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17565027Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019193s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/9622546
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17565027
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019193s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/9622546
Methacholine (trade name Provocholine) is a synthetic choline ester that acts as a muscarinic receptor agonist. Methacholine is primarily used to diagnose bronchial hyperreactivity, which is the hallmark of asthma and also occurs in chronic obstructive pulmonary disease. This is accomplished through the bronchial challenge test, or methacholine challenge, in which a subject inhales aerosolized methacholine, leading to bronchoconstriction.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9622546 |
|||
Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9622546 |
59.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | PROVOCHOLINE Approved UseProvocholine® (methacholine chloride powder for inhalation) is indicated for the diagnosis of bronchial airway hyperreactivity in subjects who do not have clinically apparent asthma. Launch Date1986 |
Doses
Dose | Population | Adverse events |
---|---|---|
16 mg/mL 5 times / day multiple, respiratory (max) Recommended Dose: 16 mg/mL, 5 times / day Route: respiratory Route: multiple Dose: 16 mg/mL, 5 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bronchial airway hyperreactivity Sources: Page: p.1 |
Disc. AE: Bronchoconstriction... AEs leading to discontinuation/dose reduction: Bronchoconstriction (severe) Sources: Page: p.1 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Bronchoconstriction | severe Disc. AE |
16 mg/mL 5 times / day multiple, respiratory (max) Recommended Dose: 16 mg/mL, 5 times / day Route: respiratory Route: multiple Dose: 16 mg/mL, 5 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bronchial airway hyperreactivity Sources: Page: p.1 |
PubMed
Title | Date | PubMed |
---|---|---|
Conditioned medium from hypoxic cytotrophoblasts alters arterial function. | 2001 Apr |
|
Mild exacerbations and eosinophilic inflammation in patients with stable, well-controlled asthma after 1 year of follow-up. | 2001 Apr |
|
Comparisons of peak diurnal expiratory flow variation, postbronchodilator FEV(1) responses, and methacholine inhalation challenges in the evaluation of suspected asthma. | 2001 Apr |
|
Chromosome 14 linkage analysis and mutation study of 2 serpin genes in allergic asthmatic families. | 2001 Apr |
|
Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. | 2001 Apr |
|
Gibbs sampling-based segregation analysis of asthma-associated quantitative traits in a population-based sample of nuclear families. | 2001 Apr |
|
IL-10 gene knockout attenuates allergen-induced airway hyperresponsiveness in C57BL/6 mice. | 2001 Feb |
|
Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. | 2001 Jan |
|
Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial. | 2001 Jan |
|
Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. | 2001 Jan |
|
Relaxant effect of Pimpinella anisum on isolated guinea pig tracheal chains and its possible mechanism(s). | 2001 Jan |
|
Secretion and gene expression of secretory leukocyte protease inhibitor by human airway submucosal glands. | 2001 Jan |
|
Methacholine responsiveness in infants assessed with low frequency forced oscillation and forced expiration techniques. | 2001 Jan |
|
Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma. | 2001 Jan |
|
[Asthma related to inhalation of Plantago ovata]. | 2001 Jan 13 |
|
Developmental expression of neurokinin A and functional neurokinin-2 receptors in lung. | 2001 Jun |
|
SCF-induced airway hyperreactivity is dependent on leukotriene production. | 2001 Jun |
|
Measurements of resistance by the interrupter technique and of transcutaneous partial pressure of oxygen in young children during methacholine challenge. | 2001 Mar |
|
Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma. | 2001 Mar |
|
Assessment of oxidant stress in allergic asthma by measurement of the major urinary metabolite of F2-isoprostane, 15-F2t-IsoP (8-iso-PGF2alpha). | 2001 Mar |
|
The transcription factor early growth-response factor 1 modulates tumor necrosis factor-alpha, immunoglobulin E, and airway responsiveness in mice. | 2001 Mar |
|
Temporal association between airway hyperresponsiveness and airway eosinophilia in ovalbumin-sensitized mice. | 2001 Mar |
|
Drug treatment of airway inflammation in asthma. | 2001 Mar |
|
A comparison of ovariectomy models for estrogen studies. | 2001 Mar |
|
Polycystic ovary syndrome is associated with endothelial dysfunction. | 2001 Mar 13 |
|
Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. | 2001 Mar 27 |
|
Role of K+ channels in N-acetylprocainamide-induced relaxation of bovine tracheal smooth muscle. | 2001 Mar 9 |
|
Muscarinic depression of synaptic transmission in the epileptogenic GABA withdrawal syndrome focus. | 2001 May |
|
Airway inflammation and bronchial hyperresponsiveness after Mycoplasma pneumoniae infection in a murine model. | 2001 May |
|
Occupational asthma caused by exposure to cyanoacrylate. | 2001 May |
|
Endothelial function during stimulation of renin-angiotensin system by low-sodium diet in humans. | 2001 May |
Patents
Sample Use Guides
Provocholine is inhaled using a standardized procedure. The challenge is performed by giving a subject ascending serial concentrations of Provocholine. At each concentration, five breaths are administered by a nebulizer that permits intermittent delivery time of 0.6 seconds by a breath-actuated timing device (dosimeter). At each of five inhalations of a serial concentration, the subject begins at functional residual capacity (FRC) and slowly and completely inhales the dose delivered. Within 5 minutes, FEV1 values are determined. The procedure ends either when there is a 20% or greater reduction in the FEV1 compared with the baseline sodium chloride solution value (i.e., a positive response) or if 188.88 total cumulative units have been administered and the FEV1 has been reduced by 14 % or less (i.e., a negative response). If there is a reduction of 15% to 19% in the FEV, compared with baseline, either the challenge may be repeated at that concentration or a higher concentration may be given as long as the dosage administered does not result in total cumulative units exceeding 188.88.
Route of Administration:
Respiratory
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9622546
Agonist activity of methacholine was determined using assay of accumulation of [3H]inositol monophosphate. The CHO cells were labeled in 12-well plates with 1 uCi/mL myo-[3H]inositol for 24 h. Wells contained ca. 3* 10^5 cells in a volume of 1 mL. Cells were then washed once with Hank’s balanced salt media containing 20 mM HEPES buffer (pH 7.4) and were then incubated in the buffered Hank’s media containing 10 mM LiCl at room temperature for 15 min. Muscarinic agents were then added to each well. After incubation for 1 h at 37 °C, the medium was aspirated and replaced with 750 uL of cold 20 mM aqueous formic acid. After 35 min at 4 °C, the formic acid was removed and replaced with 250 uL of 60 mM NH4OH. The inositol monophosphate in the NH4OH solution was isolated by anionexchange chromatography19 and counted for tritium in Hydrofluor scintillation fluid. Cells were treated with 0.001 - 10 uM of methacholine, EC50 was determined to be 120 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
625-19-4
Created by
admin on Sat Dec 16 06:39:18 GMT 2023 , Edited by admin on Sat Dec 16 06:39:18 GMT 2023
|
PRIMARY | |||
|
3083639
Created by
admin on Sat Dec 16 06:39:18 GMT 2023 , Edited by admin on Sat Dec 16 06:39:18 GMT 2023
|
PRIMARY | |||
|
210-879-4
Created by
admin on Sat Dec 16 06:39:18 GMT 2023 , Edited by admin on Sat Dec 16 06:39:18 GMT 2023
|
PRIMARY | |||
|
84CEW0PVDV
Created by
admin on Sat Dec 16 06:39:18 GMT 2023 , Edited by admin on Sat Dec 16 06:39:18 GMT 2023
|
PRIMARY | |||
|
281057
Created by
admin on Sat Dec 16 06:39:18 GMT 2023 , Edited by admin on Sat Dec 16 06:39:18 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD